These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38796792)

  • 21. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.
    Shi HJ; Zhou H; Ma AL; Wang L; Gao Q; Zhang N; Song HB; Bo KP; Ma W
    Br J Dermatol; 2019 Nov; 181(5):1028-1037. PubMed ID: 30822359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
    Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of fire needle therapy for blood stasis syndrome of plaque psoriasis: protocol for a randomized, single-blind, multicenter clinical trial.
    Liu L; Lu Y; Yan XN; Yang SQ; Gong LP; Li LE; Zhao YD; Yin QF; Wang RP; An YP; Huang G; Zhang JF; Sun XY; Li X; Li B
    Trials; 2020 Aug; 21(1):739. PubMed ID: 32843084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
    J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial.
    Li N; Zhao W; Xing J; Liu J; Zhang G; Zhang Y; Li Y; Liu W; Shi F; Bai Y
    BMC Complement Altern Med; 2017 May; 17(1):264. PubMed ID: 28506228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study.
    Lu W; Wang J; Zhang Y; Chang R; Zhao J
    Clin Cosmet Investig Dermatol; 2024; 17():1413-1422. PubMed ID: 38895605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
    Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
    Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
    Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
    Chan WSA; Wong Y; Oon HHB; Theng CTS; Chong WS
    Singapore Med J; 2023 Jul; 64(7):434-438. PubMed ID: 35196847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.
    Ying L; Suyun J; Yanhua L; Yunsheng L; Li D; Lin D; Chengzhi L; Bingjiang L; Furen Z; Wendi S; Jinnan L; Yu D; Guanshen D; Shi Y
    Adv Ther; 2023 Dec; 40(12):5464-5474. PubMed ID: 37824031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
    Cai L; Chen GH; Lu QJ; Zheng M; Li YZ; Chen J; Zheng J; Zhang FR; Yu JB; Yang S; Li FQ; Xiao SX; Sun QN; Xu JH; Gao XH; Fang H; Gao TW; Hao F; Liu QZ; Tu YT; Li RY; Wang BX; Deng DQ; Zheng QS; Liu HX; Zhang JZ
    Chin Med J (Engl); 2020 Nov; 133(24):2905-2909. PubMed ID: 33177393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
    Lu X; Wang W
    Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.